All the news Showing 10 of 119 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment Michael Carter / 10 August 2017 For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study – ... HCV therapy with SVR reduces the risk of several non-liver-related diseases commonly seen in people with chronic HCV Michael Carter / 06 July 2017 The risk of several non-liver complications associated with chronic hepatitis C virus (HCV) infection is reduced after interferon-based treatment that achieves a sustained virological response (SVR), investigators from the United ... Experts question Cochrane review of hepatitis C treatment Keith Alcorn / 15 June 2017 A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticised by doctors and advocates for its conclusion that there is no ... Hepatitis C virus reinfection is uncommon after being cured with DAAs Liz Highleyman / 22 May 2017 Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during three years of follow-up, researchers reported ... Children with hepatitis C respond well to sofosbuvir/ledipasvir Liz Highleyman / 22 April 2017 Almost all children with hepatitis C, aged 6 to 11 years, who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver ... Curing hepatitis C reduces cardiovascular risk Keith Alcorn / 20 April 2017 Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice ... Statins reduce risk of decompensation for people with HCV- and HBV-related cirrhosis Michael Carter / 18 April 2017 Treatment with statins reduces the risk of decompensated liver disease for people with cirrhosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), investigators from Taiwan report in the online edition ... FDA approves Harvoni and Sovaldi for adolescents with hepatitis C Liz Highleyman / 10 April 2017 The US Food and Drug Administration (FDA) on 7 April approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to 17 years. ... Results of US research suggest all people with chronic HCV need treatment to reduce mortality risk Michael Carter / 22 March 2017 All people with chronic hepatitis C virus (HCV) infection should start therapy with direct-acting antivirals, research published in the online edition of Clinical Infectious Diseases suggests. Investigators from the United States found that individuals ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... ← Prev1...23456...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive